MX2018002543A - Composiciones que comprenden compuestos de urolitina. - Google Patents
Composiciones que comprenden compuestos de urolitina.Info
- Publication number
- MX2018002543A MX2018002543A MX2018002543A MX2018002543A MX2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- urolithin
- urolithin compounds
- compounds
- provides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229930186301 urolithin Natural products 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1515387.7A GB201515387D0 (en) | 2015-08-28 | 2015-08-28 | Compositions |
| PCT/EP2016/070255 WO2017036992A1 (en) | 2015-08-28 | 2016-08-26 | Compositions comprising urolithin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018002543A true MX2018002543A (es) | 2018-06-15 |
Family
ID=54326542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002543A MX2018002543A (es) | 2015-08-28 | 2016-08-26 | Composiciones que comprenden compuestos de urolitina. |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10695320B2 (enExample) |
| EP (1) | EP3340977B1 (enExample) |
| JP (3) | JP7227003B2 (enExample) |
| KR (2) | KR102822365B1 (enExample) |
| CN (1) | CN108289879A (enExample) |
| AU (1) | AU2016314987B2 (enExample) |
| BR (1) | BR112018003745B1 (enExample) |
| CA (1) | CA2996724C (enExample) |
| ES (1) | ES2936723T3 (enExample) |
| GB (1) | GB201515387D0 (enExample) |
| MX (1) | MX2018002543A (enExample) |
| PT (1) | PT3340977T (enExample) |
| RU (1) | RU2754761C2 (enExample) |
| SG (1) | SG10202001793PA (enExample) |
| WO (1) | WO2017036992A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| WO2018162650A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Methods for improving mitophagy in subjects |
| US20210267932A1 (en) | 2018-05-15 | 2021-09-02 | University Of Louisville Research Foundation, Inc. | Compounds, compositions, methods of using, and methods for preparing compounds |
| GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
| CA3188397A1 (en) | 2020-09-25 | 2022-03-31 | Anupama Dattatreya | Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix |
| JP7541673B2 (ja) * | 2020-11-30 | 2024-08-29 | 国立研究開発法人産業技術総合研究所 | 筋ジストロフィーの抗炎症剤、筋ジストロフィーにおける抗炎症のための中心静脈栄養用組成物および筋ジストロフィーの抗炎症用食品組成物 |
| KR102623664B1 (ko) | 2020-12-10 | 2024-01-12 | 서울대학교산학협력단 | 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법 |
| CN117015530A (zh) | 2021-01-27 | 2023-11-07 | 范徳利亚股份公司 | 尿石素衍生物及其使用方法 |
| EP4085906A1 (en) * | 2021-05-06 | 2022-11-09 | Universite De Bordeaux | Composition comprising ppar-modulator and an urolithin derivative and uses thereof |
| CN113813255B (zh) * | 2021-10-20 | 2023-09-01 | 山东大学 | 尿石素a及其衍生物在肿瘤免疫治疗的应用 |
| WO2023199908A1 (ja) * | 2022-04-11 | 2023-10-19 | 株式会社ダイセル | 乳化組成物の製造方法 |
| GB202219317D0 (en) * | 2022-12-20 | 2023-02-01 | Amazentis Sa | Methods for improving mitophagy in subjects |
| EP4642448A1 (en) * | 2022-12-27 | 2025-11-05 | Indian Institute of Science | A method for the treatment of epilepsy |
| GB202316295D0 (en) | 2023-10-24 | 2023-12-06 | Amazentis Sa | Composition |
| EP4555997A1 (en) * | 2023-11-15 | 2025-05-21 | Science4Beauty Sp. z o.o. | Water-soluble composition comprising urolithin |
| GB202319994D0 (en) | 2023-12-22 | 2024-02-07 | Amazentis Sa | Compositions for use |
| KR20250158913A (ko) | 2024-04-30 | 2025-11-07 | 주식회사 파이안바이오테크놀로지 | 유로리틴을 함유하는 탈모완화제와 모발성장촉진제 |
| WO2025252771A1 (en) | 2024-06-03 | 2025-12-11 | Amazentis Sa | Urolithin combinations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| AU723797B2 (en) | 1996-03-26 | 2000-09-07 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
| WO1999053941A1 (fr) * | 1998-04-15 | 1999-10-28 | Shionogi & Co., Ltd. | Preparations orales contenant des derives de trh |
| AU2681300A (en) | 1999-02-22 | 2000-09-14 | Elan Corporation, Plc | Solid oral dosage form containing an enhancer |
| US6623734B2 (en) * | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
| US20050282781A1 (en) | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
| JP5147239B2 (ja) | 2004-09-29 | 2013-02-20 | 三栄源エフ・エフ・アイ株式会社 | コエンザイムｑ１０含有乳化組成物 |
| US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| US8894993B2 (en) * | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
| EP2145904A1 (de) | 2008-07-18 | 2010-01-20 | Basf Se | Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen |
| CA2737456C (en) | 2008-09-17 | 2017-05-23 | Chiasma Inc. | Pharmaceutical compositions and related methods of delivery |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| RU2657750C1 (ru) | 2010-03-19 | 2018-06-15 | Бостон Байомедикал, Инк. | Новые способы направленного воздействия на раковые стволовые клетки |
| AU2011232103B2 (en) | 2010-03-22 | 2013-10-24 | Instillo Gmbh | Method and device for producing microparticles or nanoparticles |
| CA2796494A1 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical composition |
| JP2013544829A (ja) | 2010-11-24 | 2013-12-19 | エクセリクシス， インク． | ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法 |
| JP2012111712A (ja) | 2010-11-25 | 2012-06-14 | Toyo Capsule Kk | 油性ビタミンｃ経口投与用組成物 |
| EP4578500A3 (en) * | 2010-12-23 | 2025-09-17 | Amazentis SA | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
| JP2014501784A (ja) | 2011-01-07 | 2014-01-23 | メリオン・リサーチ・Ｉｉｉ・リミテッド | 経口投与用の鉄の医薬組成物 |
| CA2826884A1 (en) * | 2012-09-14 | 2014-03-14 | Natreon, Inc. | Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit |
| GB201323008D0 (en) * | 2013-12-24 | 2014-02-12 | Amazentis As | Compounds and uses thereof |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515387D0 (en) | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
-
2015
- 2015-08-28 GB GBGB1515387.7A patent/GB201515387D0/en not_active Ceased
-
2016
- 2016-08-26 US US15/757,293 patent/US10695320B2/en active Active
- 2016-08-26 EP EP16757263.5A patent/EP3340977B1/en active Active
- 2016-08-26 MX MX2018002543A patent/MX2018002543A/es unknown
- 2016-08-26 SG SG10202001793PA patent/SG10202001793PA/en unknown
- 2016-08-26 PT PT167572635T patent/PT3340977T/pt unknown
- 2016-08-26 KR KR1020247012842A patent/KR102822365B1/ko active Active
- 2016-08-26 CA CA2996724A patent/CA2996724C/en active Active
- 2016-08-26 BR BR112018003745-1A patent/BR112018003745B1/pt active IP Right Grant
- 2016-08-26 ES ES16757263T patent/ES2936723T3/es active Active
- 2016-08-26 RU RU2018108136A patent/RU2754761C2/ru active
- 2016-08-26 KR KR1020187007291A patent/KR102660005B1/ko active Active
- 2016-08-26 WO PCT/EP2016/070255 patent/WO2017036992A1/en not_active Ceased
- 2016-08-26 JP JP2018529732A patent/JP7227003B2/ja active Active
- 2016-08-26 AU AU2016314987A patent/AU2016314987B2/en active Active
- 2016-08-26 CN CN201680050456.6A patent/CN108289879A/zh active Pending
-
2020
- 2020-06-15 US US16/901,182 patent/US11337957B2/en active Active
-
2022
- 2022-05-05 US US17/737,605 patent/US11925616B2/en active Active
- 2022-09-12 JP JP2022144671A patent/JP2022177130A/ja active Pending
-
2024
- 2024-01-19 US US18/417,794 patent/US20240148690A1/en not_active Abandoned
- 2024-10-04 JP JP2024174863A patent/JP2025004129A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002543A (es) | Composiciones que comprenden compuestos de urolitina. | |
| MX2018002546A (es) | Composiciones que comprenden un compuesto de urolitina. | |
| SA517381819B1 (ar) | التعديل المناعي | |
| WO2017095944A8 (en) | Methods and compositions relating to chondrisomes from blood products | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MD20170035A2 (ro) | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice | |
| NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| MX2017009720A (es) | Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas. | |
| EP3102220C0 (en) | SYNERGIC FOOD SUPPLEMENT COMPOSITIONS FOR THE PREVENTION, TREATMENT OR REGULATION OF INFLAMMATORY DISORDERS | |
| HK1245658A1 (zh) | 可用於治疗ibd患者的营养组合物 | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| PH12018500994A1 (en) | Nutritional compositions containing butyrate and uses thereof | |
| IL259183B (en) | Food supplement and preparation for the treatment of metabolic syndrome | |
| WO2016080796A3 (ko) | 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도 | |
| SG10201811078XA (en) | Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions | |
| SG11201708045PA (en) | Methods and compositions for the treatment of cellulosic biomass and products produced thereby | |
| TR201908639T4 (tr) | Dejeneratif göz bozukluklarının önlenmesi ve veya tedavisine yönelik safran bazlı bileşimler. | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| ZA201802606B (en) | Compositions for dental varnishes and methods of making and using same | |
| PH12019550209A1 (en) | A nutritional composition for use to enhance attention and/or reduce impulsivity | |
| WO2016109002A3 (en) | Methods and compositions for the treatment of radiation-related disorders | |
| WO2016135456A3 (en) | A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy | |
| MY188896A (en) | Methods and compositions for reducing digestive/absorptive rates and ratio of food/drinks or reducing a digestive solution | |
| HK1255053A1 (zh) | 用於抑制癌症干细胞的组合物和方法 | |
| PL413830A1 (pl) | Kompleks laktoferyny z jonami manganu, sposób jego otrzymywania, zastosowanie kompleksu oraz kompozycja farmaceutyczna zawierająca kompleks laktoferyny i jonów manganu |